Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase ...

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the ...

"The early safety profile and clinical activity results from this study are encouraging,” said Jay Raman, M.D., Professor and Chair of Urology, and Professor of Surgery, Penn State Cancer ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Society of Urologic Oncology (SUO) Session. Dr. Bernard ...

UroGen Pharma (URGN) announced new data from the OPTIMA II Phase 2b study of UGN-102 for intravesical solution demonstrate clinically ...

Prostate enlargement is an abnormal enlargement of the prostate gland causing variable degrees of bladder outlet obstruction.

Prostate enlargement is an abnormal enlargement of the prostate gland causing variable degrees of bladder outlet obstruction.

Transurethral resection of bladder tumour (TURBT) is the gold standard for diagnosing and risk-stratifying bladder cancer. Accurate and comprehensive ... and quality improvement in TURBT procedures, ...